Table 1.
Baseline characteristics of patients
| Overall | Placebo | 30‐g FMT | 60‐g FMT | p | |
|---|---|---|---|---|---|
| Number | 142 | 48 | 50 | 44 | |
| Age (y) | 40.1 ± 13.1 | 41.4 ± 13.6 | 38.9 ± 12.4 | 38.9 ± 13.4 | .665 |
| Sex, female/male | 118/24 | 42/6 | 38/12 | 38/6 | .248 |
| IBS‐D | 52 | 16 | 20 | 16 | |
| IBS‐C | 54 | 21 | 17 | 16 | .888 |
| IBS‐M | 36 | 11 | 13 | 12 | |
| IBS duration (y) | 15.5 ± 7.9 | 14.5 ± 8.0 | 17.2 ± 9.3 | 14.7 ± 5.7 | .322 |
| IBS‐SSS score | 311.5 ± 77.0 | 310.5 ± 73.8 | 313.3 ± 76.7 | 310.6 ± 82.4 | .989 |
| Patients with MSS | 59 (41.5%) | 20 (41.7%) | 21 (42%) | 18 (40.9%) | .997 |
| Patients with SSS | 83 (58.5%) | 28 (58.3%) | 29 (58%) | 26 (59.1%) | .998 |
| FAS score | 31.5 ± 5.0 | 30.6 ± 4.4 | 31.4 ± 5.3 | 31.4 ± 5.1 | .976 |
| Dysbiosis index | 2.8 ± 1.1 | 2.7 ± 1.1 | 2.8 ± 1.0 | 2.9 ± 1.0 | .781 |
| Patients with dysbiosis | 64% | 67% | 57% | 67% | .578 |
| PPI medication | 55 (38.7%) | 19 (39.6%) | 18 (36.0%) | 18 (40.9%) | .878 |
| Birth control medication | 84 (59.1%) | 25 (52.1%) | 29 (58.0%) | 30 (68.2%) | .286 |
| Antimigraine medication | 10 (7.0%) | 3 (6.2%) | 4 (8.0%) | 3 (6.3%) | .942 |
| Medication against asthma/allergies | 18 (12.7%) | 6 (12.5%) | 7 (14.0%) | 5 (11.6%) | .928 |
| Medication with levothyroxine | 3 (2.1%) | 1 (2.1%) | 0 (0%) | 2 (4.5%) | .311 |
| Medication with heart/vascular drugs | 6 (4.2%) | 3 (6.3%) | 2 (4.0%) | 1 (2.3%) | .635 |
Data are mean ± SD, n, %, or n (%) values.
PPI, proton‐pump inhibitor. MSS, moderate symptom severity (IBS‐SSS score between 175 and 300). SSS, severe symptom severity (IBS‐SSS score of ≥300).